Abstract

The TP73 gene is a member of the TP53 family with high structural homology to p53 and capable of transactivating p53 target genes. The TP73 gene locus which is highly conserved and complex, encodes for two classes of isoforms TAp73 (tumor suppressor isoforms containing the transactivation domain) and ΔNp73 (oncogenic isoforms, truncated and lacking the transactivation domain) with opposing effects. The balance between TAp73 and Δ Np73 isoforms and their harmony with other members of the TP73 family regulate various cellular responses such as apoptosis, autophagy, proliferation, and differentiation. The transcriptionally active isoforms of p73 are capable of inducing apoptosis in cancer cells independent of p53 status. Unlike p53, p73 is rarely mutated in cancers, however, the ratio of ΔNp73:TAp73 is frequently up-regulated in many carcinomas and is indicative of poor prognosis. Moreover, p73 is an important determinant of chemosensitivity and radiosensitivity, the two major treatment modalities for lymphoma. In the current review, we will provide an overview of recent progress discussing the role of TP73 in cancer, specifically addressing its relevance to lymphomagenesis, progression, therapy resistance, and its potential as a novel therapeutic target.

Original languageEnglish (US)
Pages (from-to)432-439
Number of pages8
JournalCurrent Molecular Medicine
Volume14
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Non-Hodgkin's Lymphoma
Protein Isoforms
Genes
Transcriptional Activation
Neoplasms
Apoptosis
Radiation Tolerance
p53 Genes
Autophagy
Tumors
Lymphoma
Cells
Carcinoma
Therapeutics

Keywords

  • Lymphoma
  • P73
  • Pathogenesis
  • Treatment

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

TP73, an under-appreciated player in non-hodgkin lymphoma pathogenesis and management. / Hassan, H. M.; Dave, Bhavana J; Singh, Rakesh K.

In: Current Molecular Medicine, Vol. 14, No. 4, 01.01.2014, p. 432-439.

Research output: Contribution to journalArticle

@article{2273bab4efd14fccb0d672e1c64c24fd,
title = "TP73, an under-appreciated player in non-hodgkin lymphoma pathogenesis and management",
abstract = "The TP73 gene is a member of the TP53 family with high structural homology to p53 and capable of transactivating p53 target genes. The TP73 gene locus which is highly conserved and complex, encodes for two classes of isoforms TAp73 (tumor suppressor isoforms containing the transactivation domain) and ΔNp73 (oncogenic isoforms, truncated and lacking the transactivation domain) with opposing effects. The balance between TAp73 and Δ Np73 isoforms and their harmony with other members of the TP73 family regulate various cellular responses such as apoptosis, autophagy, proliferation, and differentiation. The transcriptionally active isoforms of p73 are capable of inducing apoptosis in cancer cells independent of p53 status. Unlike p53, p73 is rarely mutated in cancers, however, the ratio of ΔNp73:TAp73 is frequently up-regulated in many carcinomas and is indicative of poor prognosis. Moreover, p73 is an important determinant of chemosensitivity and radiosensitivity, the two major treatment modalities for lymphoma. In the current review, we will provide an overview of recent progress discussing the role of TP73 in cancer, specifically addressing its relevance to lymphomagenesis, progression, therapy resistance, and its potential as a novel therapeutic target.",
keywords = "Lymphoma, P73, Pathogenesis, Treatment",
author = "Hassan, {H. M.} and Dave, {Bhavana J} and Singh, {Rakesh K}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/1566524014666140414204458",
language = "English (US)",
volume = "14",
pages = "432--439",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - TP73, an under-appreciated player in non-hodgkin lymphoma pathogenesis and management

AU - Hassan, H. M.

AU - Dave, Bhavana J

AU - Singh, Rakesh K

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The TP73 gene is a member of the TP53 family with high structural homology to p53 and capable of transactivating p53 target genes. The TP73 gene locus which is highly conserved and complex, encodes for two classes of isoforms TAp73 (tumor suppressor isoforms containing the transactivation domain) and ΔNp73 (oncogenic isoforms, truncated and lacking the transactivation domain) with opposing effects. The balance between TAp73 and Δ Np73 isoforms and their harmony with other members of the TP73 family regulate various cellular responses such as apoptosis, autophagy, proliferation, and differentiation. The transcriptionally active isoforms of p73 are capable of inducing apoptosis in cancer cells independent of p53 status. Unlike p53, p73 is rarely mutated in cancers, however, the ratio of ΔNp73:TAp73 is frequently up-regulated in many carcinomas and is indicative of poor prognosis. Moreover, p73 is an important determinant of chemosensitivity and radiosensitivity, the two major treatment modalities for lymphoma. In the current review, we will provide an overview of recent progress discussing the role of TP73 in cancer, specifically addressing its relevance to lymphomagenesis, progression, therapy resistance, and its potential as a novel therapeutic target.

AB - The TP73 gene is a member of the TP53 family with high structural homology to p53 and capable of transactivating p53 target genes. The TP73 gene locus which is highly conserved and complex, encodes for two classes of isoforms TAp73 (tumor suppressor isoforms containing the transactivation domain) and ΔNp73 (oncogenic isoforms, truncated and lacking the transactivation domain) with opposing effects. The balance between TAp73 and Δ Np73 isoforms and their harmony with other members of the TP73 family regulate various cellular responses such as apoptosis, autophagy, proliferation, and differentiation. The transcriptionally active isoforms of p73 are capable of inducing apoptosis in cancer cells independent of p53 status. Unlike p53, p73 is rarely mutated in cancers, however, the ratio of ΔNp73:TAp73 is frequently up-regulated in many carcinomas and is indicative of poor prognosis. Moreover, p73 is an important determinant of chemosensitivity and radiosensitivity, the two major treatment modalities for lymphoma. In the current review, we will provide an overview of recent progress discussing the role of TP73 in cancer, specifically addressing its relevance to lymphomagenesis, progression, therapy resistance, and its potential as a novel therapeutic target.

KW - Lymphoma

KW - P73

KW - Pathogenesis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84904070631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904070631&partnerID=8YFLogxK

U2 - 10.2174/1566524014666140414204458

DO - 10.2174/1566524014666140414204458

M3 - Article

C2 - 24730526

AN - SCOPUS:84904070631

VL - 14

SP - 432

EP - 439

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 4

ER -